Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Sep 24.
doi: 10.1111/all.70061. Online ahead of print.

Biologics to Treat Atopic Dermatitis: Effectiveness, Safety, and Future Directions

Marjolein S de Bruin-Weller  1 , Celeste M Boesjes  1 , Roselie A Achten  1 , Lisa A Beck  2 , Alan D Irvine  3 , Christian Vestergaard  4 , Marlies de Graaf  1 , Femke van Wijk  5 , Daphne S Bakker  1 , Stephan Weidinger  6
Affiliations
Review

Biologics to Treat Atopic Dermatitis: Effectiveness, Safety, and Future Directions

Marjolein S de Bruin-Weller et al. Allergy. .

Abstract

Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases worldwide. The clinical presentation of AD is heterogeneous and is characterized by a relapsing and remitting course. Most patients suffer from mild AD while approximately 5% to 20% experience severe disease activity, which often requires systemic treatment. Before 2017, systemic treatment options were limited to broad immunosuppressants, which often had significant toxicity and limited effectiveness. Advances in understanding AD pathophysiology have led to the development of targeted biologic therapies, including dupilumab, tralokinumab, lebrikizumab, and nemolizumab. These monoclonal antibodies specifically block key pro-inflammatory cytokines involved in AD, improving disease control and symptom relief. Dupilumab, the first approved biologic, inhibits IL-4 and IL-13 signaling, while tralokinumab and lebrikizumab selectively block IL-13. Nemolizumab targets IL-31, which plays a crucial role in pruritus. This review summarizes primarily real-world data on the effectiveness and safety of these biologics, providing clinical guidance for their use and management of side effects. It also briefly discusses promising therapeutic targets currently in phase 3 trials.

Keywords: atopic dermatitis; biologics; dermatology.

PubMed Disclaimer

References

    1. J. I. Silverberg, S. Barbarot, A. Gadkari, et al., “Atopic Dermatitis in the Pediatric Population: A Cross‐Sectional, International Epidemiologic Study,” Annals of Allergy, Asthma & Immunology 126, no. 4 (2021): 417–428.e2.
    1. S. Barbarot, S. Auziere, A. Gadkari, et al., “Epidemiology of Atopic Dermatitis in Adults: Results From an International Survey,” Allergy 73, no. 6 (2018): 1284–1293.
    1. S. M. Langan, A. D. Irvine, and S. Weidinger, “Atopic Dermatitis,” Lancet 396, no. 10247 (2020): 345–360.
    1. R. Chovatiya and J. I. Silverberg, “Evaluating the Longitudinal Course of Atopic Dermatitis: Implications for Clinical Practice,” American Journal of Clinical Dermatology 23, no. 4 (2022): 459–468.
    1. N. Maksimovic, S. Janković, J. Marinković, L. K. Sekulović, Z. Zivković, and V. T. Spirić, “Health‐Related Quality of Life in Patients With Atopic Dermatitis,” Journal of Dermatology 39, no. 1 (2012): 42–47.

LinkOut - more resources